Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM67PWD)

• Drug Name: Etilefrine Drug Info
• Synonyms: etilefrine hydrochloride; 943-17-9; Etilefrine HCl; Circupon; Kertasin; Effontil; 534-87-2; 3-[2-(ethylamino)-1-hydroxyethyl]phenol hydrochloride; Effortilvet; Phetasin; Updormin; Pulsamin; Apocretin; Phetanol; Funasol; Ethyl adrianol; Tonus-Forte; Etilefrin Hydrochloride; Eti-Puren; 3-(2-(Ethylamino)-1-hydroxyethyl)phenol hydrochloride; 2-Ethylamino-1-(3-hydroxyphenyl)ethanol Hydrochloride; Etilefrine hydrochloride (TN); dl-Effortil hydrochloride; Ethylephrine hydrochloride; dl-Etilefrin hydrochloride; dl-N-Ethylnorphenylephrine h

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 3306
  ChEBI ID: CHEBI:91518
  CAS Number: CAS 709-55-7
  TTD Drug ID: DM67PWD
  VARIDT Drug ID: DR00028

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor (ADR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Celiprolol hcl	DMD5LBX	Hypertension	BA00-BA04	Approved	[3]
Ovine corticotropin-releasing hormone	DME0F98	Cushing disease	5A70	Approved	[1]
Befunolol hci	DM8WCXM	Glaucoma/ocular hypertension	9C61	Approved	[3]
Oxilofrine	DMRKOS1	Orthostatic hypotension	BA21	Approved	[1]
Terbutyline	DMVPWLZ	Hypertension	BA00-BA04	Approved	[1]
Guanadrel Sulfate	DM6S157	Hypertension	BA00-BA04	Approved	[4]
Dabelotine	DMP2SGN	Cognitive impairment	6D71	Phase 3	[5]
AR08	DM93CTQ	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[6]
PMID30124346-Compound-60TABLE5	DM3QX0R	Dyskinesia	MB47.4	Patented	[7]
AIR-Epinephrine	DMGAERX	Allergy	4A80-4A85	Discontinued in Phase 1	[8]

Drug(s) Transported By Organic cation transporter 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[9]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[10]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[11]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[9]
Entecavir	DM7VTQO	Hepatitis B virus infection	1E51.0	Approved	[12]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[10]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[10]
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[13]
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[14]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[15]

Drug(s) Affected By Solute carrier family 22 member 3 (SLC22A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[16]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[16]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[16]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[18]
Phenoxybenzamine	DM8KSQH	Malignant essential hypertension	BA00	Approved	[19]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[22]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[23]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor (ADR)	TTVIREA	NOUNIPROTAC	Modulator	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 3 (SLC22A3)	DT6201N	S22A3_HUMAN	Substrate	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Regulation of Drug Effects	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
• [3] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
• [6] Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
• [7] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [8] Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500.
• [9] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [10] Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
• [11] Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
• [12] Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
• [13] Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
• [14] Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
• [15] Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
• [16] Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
• [17] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [18] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [19] Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
• [20] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [21] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [22] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [23] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.